CVGBM
Alternative Names: CV-09050101; CV09050101 mRNA vaccine - CureVacLatest Information Update: 10 Nov 2023
At a glance
- Originator CureVac
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 20 Sep 2023 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
- 05 May 2023 Phase-I clinical trials in Glioblastoma (Adjuvant therapy) in Netherlands (IM) (NCT05938387)
- 05 May 2023 Phase-I clinical trials in Glioblastoma (Adjuvant therapy) in Belgium (IM) (NCT05938387)